ketorolac has been researched along with Body Weight in 12 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Finally, the simultaneous increase in CL and Vss resulted in similar estimates for elimination half-life in both unpaired and paired analysis." | 6.84 | Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period. ( Allegaert, K; De Hoon, J; Deprest, J; Kulo, A; Maleškić, S; Smits, A; Van Calsteren, K; Van de Velde, M; Verbesselt, R, 2017) |
| "Caffeine or ketorolac decrease the risk of retinopathy of prematurity and may act synergistically to improve beneficial effect." | 3.83 | Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathy. ( Ahmad, T; Aranda, JV; Beharry, KD; Bronshtein, V; Cai, CL; Lazzaro, DR; Sadeh, J; Valencia, GB, 2016) |
| "Only body weight influenced the PK parameters for R(+) and S(-) ketorolac." | 3.81 | The enantioselective population pharmacokinetics of intravenous ketorolac in children using a stereoselective assay suitable for microanalysis. ( Cameron, GA; Engelhardt, T; Hawwa, AF; McLay, JS; Mohammed, BS, 2015) |
| " Finally, the simultaneous increase in CL and Vss resulted in similar estimates for elimination half-life in both unpaired and paired analysis." | 2.84 | Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period. ( Allegaert, K; De Hoon, J; Deprest, J; Kulo, A; Maleškić, S; Smits, A; Van Calsteren, K; Van de Velde, M; Verbesselt, R, 2017) |
| "Ketorolac was administered to 11." | 1.48 | Pain Management for Nonsyndromic Craniosynostosis: Adequate Analgesia in a Pediatric Cohort? ( Cho, R; Dorafshar, AH; Faateh, M; Kattail, D; Lopez, J; Macmillan, A; Musavi, L; Pedreira, R, 2018) |
| " The relationship between the main pharmacokinetic parameters [viz." | 1.37 | Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach. ( Gilibili, RR; Mullangi, R; Srinivas, NR, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hennig, R | 1 |
| Albawardi, A | 1 |
| Almarzooqi, S | 1 |
| Haneefa, S | 1 |
| Imbaraj, E | 1 |
| Zaaba, NE | 1 |
| Nemmar, A | 1 |
| Subramanya, S | 1 |
| Maruta, H | 1 |
| Adrian, TE | 1 |
| Kattail, D | 1 |
| Macmillan, A | 1 |
| Musavi, L | 1 |
| Pedreira, R | 1 |
| Faateh, M | 1 |
| Cho, R | 1 |
| Lopez, J | 1 |
| Dorafshar, AH | 1 |
| Pezhouman, A | 1 |
| Cao, H | 1 |
| Fishbein, MC | 1 |
| Belardinelli, L | 1 |
| Weiss, JN | 1 |
| Karagueuzian, HS | 1 |
| Moradi, A | 1 |
| Kheirollahkhani, Y | 1 |
| Fatahi, P | 1 |
| Abdollahifar, MA | 1 |
| Amini, A | 1 |
| Naserzadeh, P | 1 |
| Ashtari, K | 1 |
| Ghoreishi, SK | 1 |
| Chien, S | 1 |
| Rezaei, F | 1 |
| Fridoni, M | 1 |
| Bagheri, M | 1 |
| Taheri, S | 1 |
| Bayat, M | 1 |
| Cerreta, AJ | 1 |
| Masterson, CA | 1 |
| Lewbart, GA | 1 |
| Dise, DR | 1 |
| Papich, MG | 1 |
| Schiegerl, LJ | 1 |
| Karttunen, AJ | 1 |
| Klein, W | 1 |
| Fässler, TF | 1 |
| Persson, I | 1 |
| Halim, J | 1 |
| Lind, H | 1 |
| Hansen, TW | 1 |
| Wagner, JB | 1 |
| Näslund, LÅ | 1 |
| Darakchieva, V | 1 |
| Palisaitis, J | 1 |
| Rosen, J | 1 |
| Persson, POÅ | 1 |
| Mohammed, BS | 1 |
| Engelhardt, T | 1 |
| Hawwa, AF | 1 |
| Cameron, GA | 1 |
| McLay, JS | 1 |
| Aranda, JV | 1 |
| Cai, CL | 1 |
| Ahmad, T | 1 |
| Bronshtein, V | 1 |
| Sadeh, J | 1 |
| Valencia, GB | 1 |
| Lazzaro, DR | 1 |
| Beharry, KD | 1 |
| Kulo, A | 1 |
| Smits, A | 1 |
| Maleškić, S | 1 |
| Van de Velde, M | 1 |
| Van Calsteren, K | 1 |
| De Hoon, J | 1 |
| Verbesselt, R | 1 |
| Deprest, J | 1 |
| Allegaert, K | 1 |
| Gilibili, RR | 1 |
| Mullangi, R | 1 |
| Srinivas, NR | 1 |
| Yaksh, TL | 1 |
| Horais, KA | 1 |
| Tozier, N | 1 |
| Rathbun, M | 1 |
| Richter, P | 1 |
| Rossi, S | 1 |
| Grafe, M | 1 |
| Tong, C | 1 |
| Meschter, C | 1 |
| Cline, JM | 1 |
| Eisenach, J | 1 |
| Hsieh, YC | 1 |
| Liang, WY | 1 |
| Tsai, SK | 1 |
| Wong, CS | 1 |
| Davis, CP | 1 |
| Torre, PR | 1 |
| Schafer, NC | 1 |
| Dave, B | 1 |
| Bass, B | 1 |
| Parke, TJ | 1 |
| Lowson, SM | 1 |
| Uncles, DR | 1 |
| Daughtery, MO | 1 |
| Sitzman, BT | 1 |
| Ho, ML | 1 |
| Chang, JK | 1 |
| Wang, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections: a Prospective Double-Blinded Randomized Trial[NCT04895280] | Phase 4 | 400 participants (Anticipated) | Interventional | 2024-04-30 | Not yet recruiting | ||
| Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial[NCT04115644] | Phase 4 | 82 participants (Actual) | Interventional | 2017-05-01 | Terminated (stopped due to Covid-19 and we failed to submit annual report for 2017 and 2018) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pain as measured by the Visual Analog Scale after first injection. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Baseline - immediately after the injection
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.197 |
| Group 2 (Ketorolac) | 3.577 |
| Group 3 (Kenalog) | 3.677 |
Pain as measured by the Visual Analog Scale prior to first injection. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Baseline - pre-injection
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 5.77 |
| Group 2 (Ketorolac) | 4.57 |
| Group 3 (Kenalog) | 4.67 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Day 2
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 2.347 |
| Group 2 (Ketorolac) | 2.837 |
| Group 3 (Kenalog) | 2.67 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 1
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.397 |
| Group 2 (Ketorolac) | 3.7 |
| Group 3 (Kenalog) | 3.257 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 12
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.447 |
| Group 2 (Ketorolac) | 1.417 |
| Group 3 (Kenalog) | 2.027 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 2
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.547 |
| Group 2 (Ketorolac) | 2.67 |
| Group 3 (Kenalog) | 2.57 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 4
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.547 |
| Group 2 (Ketorolac) | 2.67 |
| Group 3 (Kenalog) | 2.317 |
Pain as measured by the Visual Analog Scale. The visual analog scale is a 0-10 scale, 0 being no pain, 10 being unbearable pain. (NCT04115644)
Timeframe: Week 6
| Intervention | score on a scale (Mean) |
|---|---|
| Group 1 (Control) | 3.357 |
| Group 2 (Ketorolac) | 2.757 |
| Group 3 (Kenalog) | 2.687 |
3 trials available for ketorolac and Body Weight
| Article | Year |
|---|---|
Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period.
Topics: Administration, Intravenous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Case-Contr | 2017 |
Ketorolac as a rapid and effective treatment of migraine headache: evaluations by patients.
Topics: Acute Disease; Adult; Analgesics; Body Weight; Emergency Service, Hospital; Female; Humans; Injectio | 1993 |
Pre-emptive versus post-surgical administration of ketorolac for hysterectomy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic | 1995 |
9 other studies available for ketorolac and Body Weight
| Article | Year |
|---|---|
1,2,3-Triazolyl ester of ketorolac (15K), a potent PAK1 blocker, inhibits both growth and metastasis of orthotopic human pancreatic cancer xenografts in mice.
Topics: Animals; Body Weight; Cell Line, Tumor; Cell Proliferation; Esters; Hemodynamics; Humans; Inhibitory | 2019 |
Pain Management for Nonsyndromic Craniosynostosis: Adequate Analgesia in a Pediatric Cohort?
Topics: Age Factors; Analgesia; Analgesics, Non-Narcotic; Analgesics, Opioid; Body Weight; Child, Preschool; | 2018 |
Topics: Analgesia; Analgesics; Analysis of Variance; Animals; Bacteria; Body Weight; Chromatography, High Pr | 2018 |
The enantioselective population pharmacokinetics of intravenous ketorolac in children using a stereoselective assay suitable for microanalysis.
Topics: Administration, Intravenous; Adolescent; Body Weight; Child; Child, Preschool; Female; Humans; Infan | 2015 |
Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathy.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Apyrase; Arteries; Body Weight; | 2016 |
Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach.
Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Brain; Cerebrovascular Ci | 2011 |
Intrathecal ketorolac in dogs and rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Dogs; Dose-Response Relationship, Dru | 2004 |
Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Injections, Spinal; Ketorolac; Male; | 2005 |
Effects of ketorolac on bone repair: A radiographic study in modeled demineralized bone matrix grafted rabbits.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bone Matrix | 1998 |
Effects of ketorolac on bone repair: A radiographic study in modeled demineralized bone matrix grafted rabbits.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bone Matrix | 1998 |
Effects of ketorolac on bone repair: A radiographic study in modeled demineralized bone matrix grafted rabbits.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bone Matrix | 1998 |
Effects of ketorolac on bone repair: A radiographic study in modeled demineralized bone matrix grafted rabbits.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bone Matrix | 1998 |